Saturday 17 October 2026
Export XCUR’s income statement to Excel — free account
Exicure, Inc.
XCUR Healthcare Biotechnology
Exicure, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $500,000.00, down 98.3% from fiscal 2022. In the quarter to June 2026, EPS grew 56.1% and free cash flow grew 65.4%, each against the same quarter a year earlier.
1.11
0.01
−0.89%
Follow XCUR
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | 3 | 5 | 3 | — | — | — | — | — |
P/E ratio |
0.22 | 0.22 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | — |
Altman Z-Score |
— | — | 7.09 | 1.98 | 1.10 | (6.48) | (8.57) | — | (18.31) | — |
P/S ratio |
16.64 | 16.64 | 1,234.35 | 127.14 | 9.28 | 0.00 | 0.22 | — | 1.04 | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 701.19 | 0.00 | 0.00 | 0.00 | — | 0.00 | — |
Altman Z″-Score (non-manufacturers) |
(6.20) | 1.63 | (2.67) | 3.25 | 1.26 | (13.84) | (20.43) | — | (43.13) | — |
P/Operating CF |
(26.23) | (26.23) | (24.43) | 10.75 | (13.06) | (1.30) | (0.87) | — | (33.05) | — |
Beneish M-Score |
— | 6.01 | (12.70) | 6.29 | 19.50 | — | — | — | — | — |
P/B ratio |
7.47 | 7.47 | 6.95 | 2.04 | 2.51 | 1.59 | 0.42 | — | 4.12 | — |
Price to Tangible BV |
7.47 | 7.47 | 6.95 | 2.04 | 2.51 | 1.59 | 0.42 | — | 4.12 | — |
EV/Sales |
14.42 | 14.42 | 1,095.22 | 45.54 | 5.35 | 14.42 | 0.18 | — | 0.85 | — |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.12 | 10.11 | — | 0.00 | — |
EV/Operating CF |
(6.06) | (6.06) | (6.63) | 44.81 | (2.26) | 0.20 | (0.14) | — | (7.85) | — |
EV/FCF |
(5.75) | (5.75) | (6.53) | 251.14 | (2.10) | 0.19 | (0.14) | — | (11.49) | — |
Quick Ratio |
1.62 | 7.69 | 12.86 | 3.56 | 5.98 | 1.15 | 5.23 | 0.33 | 4.24 | 0.98 |
Current Ratio |
1.65 | 8.24 | 13.54 | 3.63 | 6.29 | 1.28 | 6.13 | 0.81 | 4.45 | 1.19 |
Net Debt/EBITDA |
0.88 | 2.09 | 1.00 | 4.11 | 2.77 | 0.54 | (17.15) | 0.06 | 1.10 | 0.99 |
Debt/Assets |
27.54% | 16.75% | 17.13% | 4.36% | 16.74% | 10.60% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
2.32 | 0.24 | 0.24 | 0.06 | 0.27 | 0.61 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.04 | 0.39 | 0.00 | 0.02 | 0.15 | (0.01) | 0.65 | 0.00 | 0.04 | 0.00 |
Operating CF/Net income |
0.30 | 1.80 | 0.87 | (0.05) | 1.59 | 0.54 | 13.81 | 0.61 | 0.30 | 1.73 |
Capex/Depreciation |
(1.06) | (2.20) | (0.21) | (1.19) | (1.69) | (0.43) | 0.08 | 0.67 | 0.00 | 0.09 |
Interest Coverage |
(22.32) | (13.09) | (32.47) | (33.86) | (44.39) | (36.99) | (3.08) | — | (679.56) | (4,233.00) |
| 167.67% | 108.98% | (109.53%) | (51.73%) | (34.68%) | (176.25%) | (19.74%) | (188.43%) | (197.92%) | (92.47%) | |
| (68.36%) | (44.43%) | (77.63%) | (36.53%) | (22.87%) | (77.55%) | (5.86%) | (96.91%) | (72.84%) | (34.00%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (18.04%) | (423.14%) | 0.00% | (1,469.79%) |
Return on Tangible Assets |
(202.02%) | (43.01%) | (84.00%) | (31.39%) | (32.16%) | (473.92%) | (23.60%) | 3,915.28% | (91.28%) | (474.66%) |
Average Days of Receivables |
5.28 | 1.13 | 9.28 | 9.86 | 0.24 | 0.00 | 0.00 | 0.00 | 380.33 | 0.00 |
Research and Development Expense of Revenue |
1,318.44% | 134.58% | 11,965.25% | 1,492.28% | 193.19% | (10,140.58%) | 68.57% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
341.60% | 72.50% | 6,625.42% | 661.50% | 59.92% | (2,709.52%) | 37.78% | 0.00% | 1,089.80% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.58 |
Share Based Compensation of Revenue |
65.83% | 15.04% | 1,533.05% | 141.98% | 13.15% | (608.49%) | 4.75% | 0.00% | 4.40% | 0.00% |
Graham Net Nets |
0.12 | 0.12 | 0.14 | 0.47 | 0.31 | (0.56) | 0.26 | — | 0.19 | — |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | — |
Earnings Yield |
464.08% | 464.08% | (15.39%) | (16.07%) | (16.40%) | (356.80%) | (51.26%) | — | (35.19%) | — |
Free Cash Flow Yield |
(15.07%) | (15.07%) | (13.58%) | 0.14% | (27.52%) | (199.91%) | (560.41%) | — | (7.12%) | — |
Revenue per Share |
1,295.00 | 144.20 | 0.43 | 3.37 | 28.60 | (0.82) | 31.20 | 0.00 | 0.24 | 0.00 |
Operating CF per Share |
(6,312.50) | (293.61) | (71.04) | 3.43 | (67.61) | (58.94) | (38.60) | (6.46) | (1.42) | (1.36) |
Capex per Share |
(492.50) | (13.74) | (0.34) | (2.82) | (5.46) | (1.64) | 0.21 | 0.58 | 0.00 | 0.01 |
Free Cash Flow per Share |
(6,805.00) | (307.34) | (71.39) | 0.61 | (73.07) | (60.57) | (38.39) | (5.89) | (1.42) | (1.35) |
Cash per Share |
24,528.75 | 382.26 | 95.76 | 288.43 | 141.32 | 66.25 | 9.28 | 0.51 | 6.12 | 0.59 |
Shareholders Equity per Share |
3,060.00 | 296.37 | 76.38 | 210.22 | 105.90 | 19.01 | 16.15 | 1.89 | 3.31 | 0.62 |
Interest Debt per Share |
0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
3,060.00 | 296.37 | 76.38 | 210.22 | 105.90 | 19.01 | 16.15 | 1.89 | 3.31 | 0.62 |
Free Cash Flow |
(5.44) | (20.71) | (19.58) | 0.24 | (42.44) | (35.79) | (35.46) | (9.43) | (2.91) | (8.51) |
Working Capital |
7.88 | 24.28 | 25.62 | 81.69 | 72.59 | 9.60 | 8.41 | (0.49) | 10.60 | 0.74 |
Capital Expenditures |
(0.39) | (0.93) | (0.09) | (1.08) | (3.17) | (0.97) | 0.20 | 0.92 | — | 0.04 |
Net Current Asset Value |
1.91 | 18.63 | 19.86 | 78.26 | 47.38 | (9.97) | 1.65 | (6.52) | 5.39 | (5.49) |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.11 | 0.00 | — | 0.00 | — |
Capex to Sales |
0.38 | 0.10 | 0.80 | 0.83 | 0.19 | (2.00) | (0.01) | 0.00 | 0.00 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.74 | 0.32 | 0.43 | 0.44 | 0.46 | 0.57 | 0.92 | 25.46 | 31.69 | 1.50 |
Cash ROIC |
(19.63%) | (40.94%) | (37.55%) | 0.12% | (26.46%) | (62.51%) | (150.91%) | (245.26%) | (15.09%) | (110.97%) |
Accounts Receivable Turnover |
46.04 | 431.96 | 7.15 | 68.21 | 722.30 | 0.00 | 0.00 | 0.00 | 1.87 | 0.00 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | — | — | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | — | — | 0.00 | 0.00 | — | — | — |
Average Receivables |
0.02 | 0.02 | 0.02 | 0.02 | 0.02 | — | — | 0.01 | 0.27 | 0.29 |
Average Payables |
0.78 | 0.78 | 0.77 | 1.16 | 1.84 | 2.64 | 1.89 | 1.00 | 1.33 | 1.36 |
Average Assets |
24.78 | 24.78 | 28.87 | 72.01 | 107.85 | 82.66 | 44.10 | 17.45 | 13.32 | 14.55 |
Average Common Equity |
(10.10) | (10.10) | 20.46 | 50.85 | 71.13 | 36.37 | 13.08 | 8.98 | 4.90 | 5.35 |
Columns are period end dates